California Institute for Regenerative Medicine

The California Institute for Regenerative Medicine (CIRM) is a state agency founded in 2004 following the approval of California Proposition 71 by 59% of voters. The initiative allocated $3 billion for stem cell research, with an additional fund approved in 2020 through Proposition 14. CIRM's core mission is to accelerate stem cell and gene therapy research to develop treatments and cures for serious diseases. The institute supports a wide range of activities, including funding clinical trials, research projects, and educational programs, primarily focusing on conditions such as cancer, diabetes, and rare diseases.

Notable affiliated individuals include Dr. Carolyn Meltzer, who serves on the CIRM Board. The institute has achieved significant milestones, including the establishment of Alpha Stem Cell Clinics and funding numerous clinical trials that have advanced the field of regenerative medicine. CIRM's impact is profound, having positioned California as a leader in stem cell research and contributing to global advancements in medical science.